Mupiderm (Mupirocin)

Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme required for protein synthesis. By blocking this step, the drug prevents the incorporation of isoleucine into bacterial proteins, halting bacterial growth and helping to clear the infection.

The dosage of Mupiderm is determined by the prescribing clinician based on the infection type, severity, patient age, and body surface area involved. Patients should follow the specific instructions provided on the prescription label.

Safety data for mupirocin in pregnancy are limited, so the product should be used only if the potential benefit justifies the potential risk. During breastfeeding, application on intact skin is generally considered low risk, but use on broken skin should be avoided and discussed with a healthcare provider.

To order Mupiderm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mupirocin, the active ingredient in Mupiderm, offers a broad spectrum against Gram‑positive bacteria, including methicillin‑resistant Staphylococcus aureus (MRSA), which many other topical agents lack. Its unique mechanism of inhibiting isoleucyl‑tRNA synthetase differentiates it from agents such as bacitracin or neomycin, providing an alternative when resistance to those drugs is a concern.

Mupiderm should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability. Keep out of reach of children.

Mupiderm is applied topically to the affected skin area. The prescribed amount is spread thinly over the lesion, usually two to three times daily, and gently rubbed in. Hands should be washed before and after application, and the treated area should be covered only if directed by a healthcare professional.

The most serious risks include allergic contact dermatitis, which may present as severe rash, swelling, or blistering, and rare systemic hypersensitivity reactions such as anaphylaxis. Patients should discontinue use and seek medical attention if they experience these symptoms.

Mupiderm should not be used by individuals with a known hypersensitivity to mupirocin or any component of the formulation. It is also contraindicated on large body surface areas, mucous membranes, or on severely compromised skin without medical supervision.